Gil Labrucherie
RezoluteAbout Gil Labrucherie
Gil Labrucherie, 54, has served as an independent director of Rezolute, Inc. since November 20, 2019 and is Chair of the Audit Committee; he is also a member of the Nominating & Governance Committee and previously served on the Compensation Committee through June 30, 2025 . He holds a J.D. from UC Berkeley Law and a B.A. from UC Davis, is a member of the State Bar of California, and a CFA charterholder; his background spans CFO/COO roles at public biotechs and corporate counsel at Wilson Sonsini .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Nektar Therapeutics | CFO; COO (from Nov 2019) | 2016–2022 | Senior operating and finance leadership at public biotech |
| Wilson Sonsini Goodrich & Rosati | Corporate Counsel | Early career | Legal foundation; corporate transactions |
| Bloom Trust (family office) | Sole trustee/executive in charge | Not specified | Oversight of real estate assets/operations |
| Valinor Pharma LLC | Director | Until Jul 2024 | Board role until acquisition by Grünenthal |
External Roles
| Organization | Role | Start Date | Notes |
|---|---|---|---|
| Septerna, Inc. | Chief Financial Officer | Jan 2025 | Public clinical-stage biotech (GPCR platform) |
| ACELYRIN, Inc. | CFO; later CFO & Chief Business Officer | Aug 2023–Dec 2025; prior CFO Jul–Nov 2022 | Public late-stage biotech focused on autoimmune diseases |
Board Governance
- Committee assignments (effective July 1, 2025): Audit Committee — Chair (Labrucherie, Fauchet, Hogenhuis); Compensation Committee — Chair Hogenhuis; members Harris, Kreher; Nominating & Governance — Chair Kreher; members Labrucherie, Fauchet .
- Independence: The Board determined Mr. Labrucherie is independent under Nasdaq Rule 5605(a)(2) .
- Financial expertise: The Board designated Mr. Labrucherie as an “audit committee financial expert” .
- Attendance: The Board met 4 times in FY2025; each director attended at least 75% of Board and committee meetings. In FY2024, the Board met 5 times; each director attended at least 75% of applicable meetings .
- Leadership structure: CEO serves as Acting Chair; independent directors provide oversight through committees and executive sessions per governance charters .
Fixed Compensation
| Component (USD) | FY2024 | FY2025 |
|---|---|---|
| Board annual retainer | $45,000 | $45,000 |
| Audit Committee Chair fee | $10,000 | $15,000 |
| Compensation Committee member fee | $7,000 | $7,000 |
| Nominating & Governance member fee | $7,000 | $7,000 |
| Total Cash Fees | $69,000 | $74,000 |
Notes: FY2024 director cash fees reflect committee roles at that time; FY2025 reflects continued Audit Chair role and membership on Nominating & Governance; Compensation Committee service through June 30, 2025 .
Performance Compensation
| Grant Date | Award Type | Shares/Options | Exercise Price | Grant-Date Fair Value | Vesting | Expiration |
|---|---|---|---|---|---|---|
| Jan 23, 2024 | Stock Options | 30,000 | $1.02 | $24,444 | Monthly over 36 months to Jan 23, 2027 | Jan 23, 2034 |
| Feb 16, 2025 | RSUs | 25,500 | — | $117,555 (25,500×$4.61) | Cliff vest Mar 1, 2026 | N/A |
| Feb 16, 2025 | Stock Options | 15,000 | $4.61 | Included in option FV | One-year to Mar 1, 2026 | Feb 16, 2035 |
| Jun 10, 2025 | RSUs | 9,000 | — | $39,510 (9,000×$4.39) | Cliff vest Jul 1, 2026 | N/A |
| Jun 10, 2025 | Stock Options | 5,000 | $4.39 | Included in option FV | One-year to Jul 1, 2026 | Jun 10, 2035 |
Aggregate FY2025 director equity values for Mr. Labrucherie: RSUs $157,065; Options $65,093; Total director compensation $296,158 .
No director PSUs or performance-conditioned vesting were disclosed; awards are time-based RSUs and options, typical of director compensation structures .
Other Directorships & Interlocks
| Entity | Type | Relationship |
|---|---|---|
| Nektar Therapeutics | Public biotech | Shared prior employer with Rezolute CEO Nevan Elam (Elam SVP; Labrucherie CFO/COO) — potential network tie, not a disclosed related-party transaction |
| Handok Inc. | Strategic investor (board observer present) | No disclosed transactions involving Mr. Labrucherie; Handok’s investments were disclosed separately . |
No other current public company directorships by Mr. Labrucherie were disclosed beyond Rezolute .
Expertise & Qualifications
- 25+ years in finance, corporate development, and legal at public biotechs; CFO and COO experience at Nektar; CFO at Septerna; CFO/CBO at ACELYRIN .
- Legal training (UC Berkeley Law) and corporate counsel experience (Wilson Sonsini) support governance and compliance oversight .
- Audit committee financial expert designation; CFA charterholder; enhances board oversight of reporting, controls, and capital markets matters .
Equity Ownership
| Measure | As of | Amount |
|---|---|---|
| Beneficial ownership (total) | Sep 22, 2025 | 164,072 shares (<1%) |
| Breakdown: shares owned (trust) | Sep 22, 2025 | 53,752 |
| Breakdown: options exercisable within 60 days | Sep 22, 2025 | 110,500 |
| Outstanding director awards (unvested RSUs) | Jun 30, 2025 | 34,500 |
| Outstanding options (vested) | Jun 30, 2025 | 107,166 |
| Outstanding options (unvested) | Jun 30, 2025 | 35,834 |
Policy alignment:
- Insider trading policy prohibits short sales, options trading/hedging, and pledging except in limited, pre-approved circumstances; no pledging by Mr. Labrucherie was disclosed in the proxy .
- Section 16 compliance: only late Form 4s noted for other directors; none for Mr. Labrucherie, indicating timely reporting .
Governance Assessment
- Strengths: Independent director; Audit Committee Chair and SEC-defined financial expert; consistent meeting attendance (≥75%); robust legal/finance expertise aligned to Rezolute’s needs; equity ownership and ongoing option exposure provide alignment .
- Risks/Watch items:
- Multiple C-suite commitments (Septerna CFO since Jan 2025; ACELYRIN through Dec 2025) could pose time-allocation considerations; monitor engagement levels versus Rezolute’s board demands .
- Network interlock with CEO via prior tenure at Nektar; not a related-party transaction but relevant to board dynamics and challenge function .
- Shift in director equity mix in FY2025 to include RSUs alongside options raises guaranteed equity versus option-only structure; typical for directors but lowers at-risk element marginally .
- Related-party/Conflicts: No related-party transactions involving Mr. Labrucherie were disclosed; Audit Committee pre-approves related-party transactions, reducing conflict risk .
Overall signal: Strong governance profile with audit leadership and independence; keep focus on time commitments and ongoing equity plan changes when assessing alignment and board effectiveness .